A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

Inclusion Criteria:

- Total testosterone level <10.4 nmol/L (300 ng/dL) at screening

- Presents with 1 or more of the following symptom(s) of ejaculatory dysfunction:
delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased
ejaculatory volume, as determined by investigator assessment

- Prostate-Specific Antigen (PSA) <4 ng/mL at screening

Exclusion Criteria:

- Sexual partner who is or becomes pregnant at any time during the study

- Premature ejaculation as determined by investigator assessment

- Currently receiving testosterone replacement therapy or have a history of
insufficient response to testosterone replacement therapy for ejaculatory dysfunction
symptoms

- Currently receiving treatment with cancer chemotherapy or antiandrogens

- History of use of estrogenizing agents

- Current use of warfarin

- History of selective serotonin reuptake inhibitor (SSRI) and/or
serotonin-norepinephrine reuptake inhibitor (SNRI) treatment in the 6 months prior to
screening

- History of frequent opioid use within 30 days prior to screening, with exception of
treatment for chronic pain as determined by investigator.

- Body Mass Index (BMI) >35 kg/m2 at screening

- Significant peripheral neuropathy affecting erectile, ejaculatory, or orgasmic
function

- Hematocrit ≥50% at screening

- Exhibit systolic blood pressure >170 mm Hg or <90 mm Hg or diastolic blood pressure
>100 mm Hg or <50 mm Hg at screening (if stress is suspected, retest under basal
conditions at screening), or have history of malignant hypertension

- History of any of the following coronary conditions within 90 days of screening:
Myocardial infarction, Coronary artery bypass graft surgery, Percutaneous coronary
intervention (eg, angioplasty or stent placement)

- Known or suspected carcinoma (or history of carcinoma) of the prostate or suspicious
nodules on digital rectal exam at screening

- Known or suspected breast cancer (or history of breast cancer) or other active cancer
(with the exception of nonmelanotic skin cancer)